کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
6156289 | 1598240 | 2016 | 13 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Controversies Regarding Lipid Management and Statin Use for Cardiovascular Risk Reduction in Patients With CKD
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
ASCVDStatin - استاتینDrug safety - ایمنی مواد مخدرcoronary heart disease - بیماری عروق کرونر قلبcardiovascular disease - بیماری قلب و عروقیAtherosclerotic cardiovascular disease - بیماری قلبی عروقی AtheroscleroticTreatment recommendations - توصیه های درمانReview - مرورMortality - مرگ ومیرCKD - نارسایی مزمن کلیهRisk score - نمره ریسکLipids - چربیهاcholesterol - کلسترولhigh density lipoprotein cholesterol - کلسترول لیپوپروتئین با چگالی بالاlow density lipoprotein cholesterol - کلسترول لیپوپروتئین با چگالی کمGuidelines - گایدلاین یا دستورالعمل
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
بیماریهای کلیوی
پیش نمایش صفحه اول مقاله
![عکس صفحه اول مقاله: Controversies Regarding Lipid Management and Statin Use for Cardiovascular Risk Reduction in Patients With CKD Controversies Regarding Lipid Management and Statin Use for Cardiovascular Risk Reduction in Patients With CKD](/preview/png/6156289.png)
چکیده انگلیسی
Adults with chronic kidney disease (CKD) are at heightened risk for dying of cardiovascular disease. Results from randomized clinical trials of statin drugs versus placebo demonstrate that statin drugs or statin plus ezetimibe reduce the absolute risk for coronary heart disease and mortality among adults with non-dialysis-dependent CKD. The Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline for lipid management in CKD recommends that adults 50 years or older with non-dialysis-dependent CKD be treated with a statin or statin plus ezetimibe regardless of low-density lipoprotein cholesterol levels. However, at least 9 guidelines published during the last 5 years address lipid management for primary and secondary prevention of atherosclerotic cardiovascular disease, and not all guidelines address the utility of lipid-lowering therapy in adults with CKD. Because most patients with CKD receive most of their clinical care from non-nephrologists, differences in recommendations for lipid-lowering therapy for cardiovascular disease prevention may negatively affect the clinical care of adults with CKD and cause confusion for both patients and providers. This review addresses the identification and management of lipid levels in patients with CKD and discusses the existing controversies regarding testing and treatment of lipid levels in the CKD population.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: American Journal of Kidney Diseases - Volume 67, Issue 6, June 2016, Pages 965-977
Journal: American Journal of Kidney Diseases - Volume 67, Issue 6, June 2016, Pages 965-977
نویسندگان
Talar PhD, Nicholas PharmD, BCPS, Benjamin DO, Julia MD, Ivan MD, Vinod MD, David MD, Kevin PhD, Alex MD, MS, Holly MD, MPH,